<unk>  (trade name Jetrea) is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.
Ocriplasmin
Prothrombinase
Anistreplase
Thrombin
Serpin
Recombinant factor VIIa
Von Willebrand factor
Prothrombin complex concentrate